Supplementary Table 1: Participant age, gender, comorbidities and therapies received
Study ID
Mean age
% male
Co-morbidities
Therapies received
Brugts 200915
59 years
78% male
19% diabetes, 47% hypertension, 51% hypercholesterolemia,
33% ACE-I or ARB, 68% beta-blocker, 55% statin.
25% previous MI, 2% previous stroke.
Byrne 200916
64 years
73% male
23% diabetes, 19% hypertension, 64% hyperlipidemia, 9%
NA
peripheral vascular disease, 7% cerebrovascular disease, 6%
previous malignancy.
Chase 20084
64 years
73% male
23% diabetes, 64% hyperlipidemia, 32% prior MI, 58%
NA
hypertension, 9% peripheral vascular disease, 7%
cerebrovascular disease, 6% malignancy.
Cosgrove
Older in
More female in
200917
transfusion
transfusion group.
More renal disease and anemia in transfusion group.
NA
group.
Dada 200918
NA
NA
NA
NA
Doyle 200819
65 years
71% male
22% diabetes, 61% hypertension, 63% hypercholesterolemia,
30% glycoprotein IIb/IIIa inhibitor.
12% peripheral vascular disease, 75% unstable angina.
Ergelen
56 years
83% male
24% diabetes, 41% hypertension, 11% history of MI.
49% tirofiban.
68 years
58% male
74% hypertension, 37% diabetes, 20% congestive heart failure,
91% aspirin, 69% intravenous heparin, 7% low molecular
20% COPD, 12% atrial fibrillation, 37% prior MI.
weight heparin, 40% ticlopidine/clopidogrel, 72%
201220
Jani 200721
1
glycoprotein IIb/IIIa inhibitors.
Jolicoeur
19% had age
200922
≥75 years
Kim 200723
72 years
74% male
45% male
15% diabetes, 49% hypertension, 12% prior MI, 3% prior heart
83% aspirin, 46% low molecular weight heparin, 31%
failure, 4% prior stroke.
thienopyridine, 15% glycoprotein IIb/IIIa inhibitors.
32% diabetes, 73% hypertension, 10% chronic renal failure, 27%
62% glycoprotein IIb/IIIa agents.
congestive heart failure, 19% COPD, 19% peripheral vascular
disease, 14% cerebrovascular accident.
Kinnaird
64 years
70% male
63% hypertension, 27% diabetes, 9% chronic renal insufficiency.
4% abciximab.
66 years
66% male
11% COPD, 10% peripheral vascular disease, 63% hypertension,
65% heparin, 9% bivalirudin, 36% glycoprotein IIb/IIIa
58% hypercholesterolemia, 44% history of coronary artery
inhibitor.
200324
Leung 201025
disease.
Maluenda
NA
NA
NA
NA
59 years
73% male
24% diabetes, 48% hypertension, 38% hyperlipidemia, 14% prior
27% aspirin, 3% thienopyridine, 9% ACE-i or ARB, 15%
MI, 3% prior stroke or transient ischemic attack, 3% peripheral
beta-blocker, 16% calcium-channel blocker, statin.
200926
Nikolsky
200927
vascular disease, 18% chronic renal insufficiency.
Robinson
201028
64 years
73% male
58% hypertension, 63% dyslipidemia, 9% peripheral vascular
NA
disease, 7% cerebrovascular disease, 22% diabetes, 6%
malignancy, 33% prior MI/congestive heart failure, 8%
pulmonary disease, 6% GI/liver disease.
2
Robinson
70 years
53% male
201229
66% hypertension, 19% peripheral vascular disease, 12%
NA
cerebrovascular disease, 36% diabetes, 11% prior malignancy,
45% prior MI/congestive heart failure, 16% chronic lung disease,
13% GI/liver disease.
Sherwood
65 years
67% male
20147
82% hypertension,79% hyperlipidemia, 35% diabetes, 13%
NA
peripheral vascular disease, 12% cerebrovascular disease, 15%
chronic lung disease.
Tajstra 201330
59 years
73% male
20% diabetes, 58% hyperlipidemia, 54% hypertension, 19% prior
75% stent implantation, 5% glycoprotein IIb/IIIa blocker.
MI.
Valenti
65 years
75% male
15% diabetes, 11% previous MI.
NA
201031
3
Supplementary Table 2: Study quality assessment
Study ID
Ascertainment of
Ascertainment of outcome
Baseline differences
Lost to follow up
Use of adjustments
Unclear.
Unclear.
Adjusted for age, gender, race, comorbidities, history
transfusion
Brugts
Independent clinical
Independent clinical
200915
events committee
events committee
of PCI, history of coronary artery bypass grafting, left
adjudicated all reported
adjudicated all reported
ventricular ejection fraction <30%, diagnosis at entry,
cardiac end points and
cardiac end points.
coronary stent placement, number of diseased vessels,
episodes of bleeding after
medication use, and allocation to xemolifiban.
enrollment.
Byrne
Data cross referenced
Data cross reference with
Unclear.
Not reported but
200916
with the Central
vital statistics data which
missing data was
Transfusion Registry
automatically entered into
imputed.
which prospectively
the British Columbia
catalogues all blood
Cardiac Registry.
Adjusted but unclear which variables.
products transfused.
Chase
The Central Transfusion
Vital statistics data are
Unclear.
514 were
Adjusted for age, BMI, creatinine, comorbidities,
20084
Registry prospectively
automatically entered into
excluded.
previous PCI, smoking history, history of dialysis,
catalogues all blood
the British Columbia
diagnosis of acute coronary syndrome, access site,
products transfused.
Cardiac Registry.
receipt of transfusion.
4
Cosgrove
Unclear.
Unclear.
200917
Dada
Unclear.
Unclear.
200918
Differences in age, gender, renal
Unclear.
Adjusted for age, sex, race, comorbidities, anemia, left
disease, anemia, glycoprotein IIb/IIIa
ventricular dysfunction, use of glycoprotein IIb/IIIa
inhibitor.
inhibitors, type of stent used, transfusion during PCI.
Differences in age, comorbidities,
Unclear.
Propensity score adjustment.
355 were
Adjusted for age, gender, urgency of PCI, pre-PCI
excluded.
shock, pre-PCI MI, body mass index, smoking status,
diabetes, hypertension, hyperlipidemia,
renal insufficiency, prior history of
PCI/CABG.
Doyle
Prospective data
Prospective data
200819
collection in Mayo Clinic
collection in Mayo Clinic
PCI database.
PCI database.
Unclear.
comorbidities, left ventricular ejection fraction,
AHA/ACC type C lesion, number of diseased coronary
vessels, prior CABG, prior PCI.
Ergelen
Data obtained from
Follow up from hospital
Differences in age, gender,
107 excluded
Adjusted for age, gender, comorbidities, three-vessel
201220
medical records.
records or interviews.
hypertension, PCI history, Mi history,
because of
disease, unsuccessful procedure, tirofiban use, time to
current smoker, Killip class.
cardiogenic
reperfusions, anemia, Killip class and RBC transfusion.
shock. 46
participants were
lost to follow up.
Jani
Data collected on
Data collected on
Differences in age, gender, current
4,313 excluded
Adjusted for nadir hemoglobin less than or equal to
200721
standardized forms.
standardized forms.
smoker, diabetes, GI bleeding, COPD,
for missing
median, congestive heart failure, history of GI
5
atrial fibrillation, prior CABG, in-
hemoglobin and
bleeding, COPD, cardiogenic shock, emergency PCI
hospital hemoglobin, cardiogenic
31 excluded
and acute MI.
shock, VT/VF, ejection fraction <40%,
because of
cardiac arrest, emergent PCI,
implausible
congestive heart failure, creatinine ≥2.0.
hemoglobins.
Jolicoeur
Transfusion was
Clinical events were
Difference in age, gender, weight,
204 were
Adjusted for age, diabetes, systolic blood pressure,
200922
prospectively recorded on
centrally adjudicated by a
diabetes, hypertension, prior MI, active
excluded who
heart rate, total ST-segment change, Killip class,
the electronic case report
blinded clinical events
smoking, prior heart failure, prior PCI,
underwent
anterior MI, recatherization and IABP.
form.
committee.
heart rate, blood pressure, serum
CABG.
creatinine, baseline hemoglobin.
Kim
In-hospital outcomes
In-hospital outcomes
Differences in history of cancer,
960 were
Multivariate model with baseline hematocrit, nadir
200723
prospectively recorded in
prospectively recorded in
baseline creatinine, hematocrit, elective,
excluded for lack
hematocrit, heparin use, smoker, renal failure, groin
a dedicated quality
a dedicated quality
urgency, heparin use and in lab
of serial
hematoma, retroperitoneal hematoma, systemic bleed,
assurance database.
assurance database.
cardiopulmonary resuscitation.
hematocrit
IABP.
measurements.
Kinnaird
Data from independent
Clinical outcomes
200324
hospital chart review.
Unclear.
Follow-up data
Adjusted for age, weight, gender, comorbidities,
obtained by telephone
available for 86%
CABG, diagnosis, use of glycoprotein IIb/IIIa, clotting
interviews conducted by
of participants in
time, use of IABP, procedural hypotension, procedural
experienced research
1 year.
time, saphenous vein graft intervention.
nurses.
6
Leung
Data collected
All-cause mortality was
Unclear.
Unclear.
Adjusted for age, gender, creatinine, comorbidities,
201025
prospectively.
collected using the Social
smoking, BMI, stable angina, prior PCI, prior CABG,
Security Master Death
priority, ejection fraction <35, cardiogenic shock,
File retrospective data.
coronary artery disease, baseline creatinine, hematocrit,
length of post-interventional stay, transfusion, heparin
use, glycoprotein IIb/IIIa, bivalirudin use,
interventional procedure, access site, sheath count/size,
closure device, IABP use, hematoma, retroperitoneal
bleed, subacute stent thrombosis.
Maluenda
Records were reviewed.
Records were reviewed.
200926
Differences in age, gender, renal failure
Unclear.
Multivariate but unclear variables in model.
Unclear.
Adjusted for age, sex, diabetes, hypertension,
and prior congestive heart failure.
Nikolsky
Clinical follow up for
Clinical follow up for
Differences in age, gender, history of
200927
events.
events.
GI bleeding, body mass index, baseline
hypercholesterolemia, current smoking, history of prior
anemia, hemoglobin, hematocrit,
MI or CABG, Killip class, baseline anemia, creatinine
platelet count, creatinine clearance,
clearance, left anterior descending artery as an infarct
chronic renal insufficiency, triple vessel
vessel, triple vessel disease, treatment with abciximab
disease, admission ACE-i and ARB and
or stent, baseline reference vessel diameter, minimal
calcium-channel blocker.
luminal diameter, final TIMI flow grade, time from the
symptom onset to first balloon inflation, admission
medications and moderate/severe bleeding.
7
Robinson
Transfusion data
Mortality data collected
Differences in age, BMI, gender,
201028
collected from British
from Ministry of Health
creatinine>90 micromol/l, stable
Columbia Central
Vital Statistics database.
angina, hypertension, dyslipidemia,
Transfusion Registry.
Unclear.
Propensity matched analysis.
Unclear.
Adjusted for age, BMI, gender, smoking history,
peripheral vascular disease,
cerebrovascular disease, diabetes,
malignancy, prior MI/congestive heart
failure, prior PCI/CABG, pulmonary
disease, GI/liver disease, vascular
access and procedural data.
Robinson
Transfusion data
Mortality data collected
Differences in age, male, chronic lung
201229
collected from British
from Ministry of Health
diseases and mean RBC transfusion
comorbidities, previous PCI/CABG, arterial access site,
Columbia Central
Vital Statistics database.
volume.
creatinine>90 mmol/L, indication for procedure, red
Transfusion Registry.
blood cell transfusion volume, platelet transfusion or
plasma/cryoprecipitate transfusion, fluoroscopy time.
Sherwood
Data collected onto
Data collected onto
Major differences in age, gender, race,
3015682
Inverse probability–weighted model included: age, sex,
20147
registry program which
registry program which
hypertension, hyperlipidemia, diabetes,
participants
race, body mass index, prior MI, prior CABG/valvular
has data quality program
has data quality program
peripheral vascular disease,
excluded.
surgery, cardiogenic shock, cardiac arrest, use of intra-
which has auditing
which has auditing
cerebrovascular disease, chronic lung
aortic balloon pump, comorbidities, tobacco use, family
program.
program.
disease, GFR, end stage renal failure
history, dialysis, glomerular filtration rate, New York
with dialysis, prior MI, prior congestive
Heart Association class IV CHF, location of lesion,
heart failure, smoking status, PCI
indication, PCI status, and hospital characteristics such
8
status, PCI indication, location of
as public vs private ownership, core-based statistical
lesion, presentation, NHYA class,
area, number of beds, PCI volume, teaching facility
cardiogenic shock, cardiac arrest, intra-
status, and region.
aortic balloon pump.
Tajstra
Clinical data were
Clinical data were
There were differences in age, gender,
201330
prospectively recorded in
prospectively recorded in
thrombolysis use, diabetes, prior MI,
coronary artery disease, initial TIMI flow grade, final
a computerized database
a computerized database
cardiogenic shock, glomerular filtration
TIMI flow grade, left ventricular ejection fraction,
and follow up was
and follow up was
rate, hemoglobin, hematocrit,
current smoking, hypertension, diabetes,
obtained by direct phone
obtained by direct phone
glycoprotein IIb/IIIa blocker, final
hyperlipidemia, cardiogenic shock, prior MI,
calls, outpatient visits and
calls, outpatient visits and
TIMI flow grade and angiographic
glycoprotein IIb/IIIa blocker, baseline anemia, baseline
from National Health
from National Health
success.
hematocrit, baseline platelet count, stent implantation,
Fund database.
Fund database.
Unclear.
Unclear.
Valenti
201031
Unclear.
Adjusted for age, male sex, anterior MI, multivessel
thrombolysis, GFR, gastrointestinal bleeding.
There were major differences in age,
Unclear.
Multivariate analysis used but unclear variables.
gender, diabetes, previous MI,
cardiogenic shock, ischemia time and
multivessel disease.
9